Therapeutic uses of inhibitors of RTP801

Details for Australian Patent Application No. 2007207479 (hide)

Owner Quark Pharmaceuticals, Inc. Silence Therapeutics AG

Inventors Feinstein, Elena; Skaliter, Rami

Agent Allens Arthur Robinson

Pub. Number AU-B-2007207479

PCT Pub. Number WO2007/084684

Priority 60/760,586 20.01.06 US; 60/796,901 01.05.06 US; 60/851,000 10.10.06 US

Filing date 18 January 2007

Wipo publication date 26 July 2007

Acceptance publication date 10 May 2012

International Classifications

C07H 21/00 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

A61K 31/70 (2006.01) - Carbohydrates

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

31 July 2008 PCT application entered the National Phase

  PCT publication WO2007/084684 Priority application(s): WO2007/084684

10 May 2012 Application Accepted

  Published as AU-B-2007207479

6 September 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007207481-Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors

2007207472-System and method for applying reduced pressure to cell culture